Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours By Ogkologos - July 21, 2025 407 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with... June 5, 2023 Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer January 24, 2022 FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with... November 20, 2025 Community Comes Together To Give Terminally Ill Father One Last Christmas... October 18, 2021 Load more HOT NEWS Foster Teen With A Passion For Painting Is Patiently Waiting For... Clinical Utility of ctDNA NGS for Detecting Actionable Alterations According ESCAT... What to Know About Navigating Cancer Care With a Disability: An... TACE-Based Treatment Combinations Effective Against Intermediate-Stage Liver Cancer
